For example, insulin-like growth factor-I receptor activation blocks doxorubicin cytotoxicity in sarcoma cells[32], and the EGFR inhibitor gefitinib sensitizes colon cancer cells to irinotecan[33]. This evidence concerns the gene IGF1R and malignant colon neoplasm.